XKRX
183490
Market cap62mUSD
Mar 25, Last price
990.00KRW
Name
Enzychem Lifesciences Corp
Chart & performance
P/E
—
P/S
1.24
EPS
—
Div yield, %
—
Shrs. gr., 5y
6.72%
Rev. gr., 5y
21.28%
Revenues
67.75b
-12.44%
Net income
-18.13b
L-17.98%
CFO
-11.01b
L+1,818.74%
Dividend
Mar 15, 20221.71 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Enzychem Lifesciences Corporation, a pharmaceutical company, primarily dedicates itself to formulating oral, small-molecule therapies aimed at addressing urgent unmet medical needs for patients in South Korea suffering from conditions in oncology, metabolic diseases, and inflammatory disorders. Furthermore, the firm is actively developing innovative treatments utilizing its EC-18 technology platform to combat chemotherapy-induced neutropenia, oral mucositis triggered by chemoradiation therapy, and acute radiation syndrome. Founded in 1999, its headquarters are situated in Seoul, South Korea.
Key people
Gi Yeong Son
Chief Executive Officer, Director
Jong Su Lee
Managing Partner
Yin Su Kang
Vice President · since 2021
Hye Gyeong Kim
Vice President, Director · since 2021
Hong Gyun Lee
Vice President
Gwang Sik Choi
Managing Director
Gap Ju Park
Managing Director
Jae Ho Choi
Assistant Managing Director
Taek Min Gwon
Internal Auditor · since 2022
Jae Han Jung
Assistant Managing Director
Hwang Bae Kang
Internal Auditor
Dong Gyun Shin
Assistant Managing Director
Tae Hun Kim
Director · since 2022
Byeong Chae Ryu
Director · since 2022
Non-Executive Independent Director
Chang Gi Hong
Non-Executive Independent Director · since 2022
Hye Yeong Oh
Non-Executive Independent Director
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||